692 related articles for article (PubMed ID: 32254090)
1. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
2. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
3. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
4. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
5. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
[TBL] [Abstract][Full Text] [Related]
6. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
7. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy.
Vijayakumar MR; Muthu MS; Singh S
Expert Opin Drug Deliv; 2013 Apr; 10(4):529-43. PubMed ID: 23316695
[TBL] [Abstract][Full Text] [Related]
8. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
10. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.
Shi D; Beasock D; Fessler A; Szebeni J; Ljubimova JY; Afonin KA; Dobrovolskaia MA
Adv Drug Deliv Rev; 2022 Jan; 180():114079. PubMed ID: 34902516
[TBL] [Abstract][Full Text] [Related]
11. Improved Targeting of Cancers with Nanotherapeutics.
Foster C; Watson A; Kaplinsky J; Kamaly N
Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
13. Smart surface coating of drug nanoparticles with cross-linkable polyethylene glycol for bio-responsive and highly efficient drug delivery.
Wei W; Zhang X; Chen X; Zhou M; Xu R; Zhang X
Nanoscale; 2016 Apr; 8(15):8118-25. PubMed ID: 27025546
[TBL] [Abstract][Full Text] [Related]
14. The effect of surface poly(ethylene glycol) length on in vivo drug delivery behaviors of polymeric nanoparticles.
Wang JL; Du XJ; Yang JX; Shen S; Li HJ; Luo YL; Iqbal S; Xu CF; Ye XD; Cao J; Wang J
Biomaterials; 2018 Nov; 182():104-113. PubMed ID: 30114562
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
Frazier N; Ghandehari H
Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
[TBL] [Abstract][Full Text] [Related]
16. Combination antitumor therapy with targeted dual-nanomedicines.
Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy.
Yao Y; Saw PE; Nie Y; Wong PP; Jiang L; Ye X; Chen J; Ding T; Xu L; Yao H; Hu H; Xu X
J Mater Chem B; 2019 Jan; 7(4):576-585. PubMed ID: 32254791
[TBL] [Abstract][Full Text] [Related]
18. Designing Stimuli-Responsive Upconversion Nanoparticles that Exploit the Tumor Microenvironment.
Ovais M; Mukherjee S; Pramanik A; Das D; Mukherjee A; Raza A; Chen C
Adv Mater; 2020 Jun; 32(22):e2000055. PubMed ID: 32227413
[TBL] [Abstract][Full Text] [Related]
19. Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery.
Fang Y; Xue J; Gao S; Lu A; Yang D; Jiang H; He Y; Shi K
Drug Deliv; 2017 Dec; 24(sup1):22-32. PubMed ID: 29069920
[TBL] [Abstract][Full Text] [Related]
20. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.
Du JZ; Mao CQ; Yuan YY; Yang XZ; Wang J
Biotechnol Adv; 2014; 32(4):789-803. PubMed ID: 23933109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
